Benefits of Digital Pathology for Clinical Trial Sponsors and Pathology Teams
Can advances in tech-enabled solutions and workflows optimize diagnostic analysis while reducing the burden on pathologists?
Get in Touch
Our Locations
At-home Self-collection of Blood Specimens for Safety Lab Testing in Clinical Trials via the Tasso+ Device
Supporting virtual clinical trials with laboratory services that focus on easing patient and site burden by way of innovative self-collection technology.
What are the opportunities for decentralized clinical trials
Hybrid and decentralized clinical trials (DCTs) are fast becoming the norm, but they often involve multiple vendors and service providers, presenting sponsors and CROs with new considerations on the...
Integrating Self-Collection Lab Panels: The Clinical Lab Perspective
With recent advancements in the self-collection of blood allowing trial participants to provide blood specimen for lab testing from the comfort of their home, Q2 Solutions’ Chuck Drucker recently...
Moving from chaos to calm: How a complete CTST solution can simplify your clinical trials
You feel like a ball of anxiety from the beginning to the end of your clinical trials. You have so many competing priorities that you don’t have time to learn new technology. You want to build...
Clinical trial consent: Using automation to get it right —every time
“We have 20,000 samples and don’t know what they’re for or where they’re from!”
Clinical trial sample and consent tracking in the Digital Age
Moving from pen and paper to automated tech
PLK3 amplification and tumor immune microenvironment of metastatic tumors are linked to adjuvant treatment outcomes in uterine serous cancer
NAR Cancer article, with contributions from Wendell Jones, PhD, Q2 Solutions GenomicsUterine serous carcinoma (USC), an aggressive variant of endometrial cancer representing approximately 10% of...
What are the key ingredients for a best practice R&D approach for tackling infectious disease?
With a renewed interest in vaccine research and development (R&D), stakeholders across the industry are rethinking their approach to the field. Biopharmaceutical companies have growing numbers of...
Balancing R&D for Disease X and common illnesses
Stakeholders from across the industry, including biopharmaceutical companies, governments, and non-profit organizations, are rethinking their pandemic readiness in light of the COVID-19 pandemic,...
